Key result
Adding an implantable cardioverter-defibrillator backup to cardiac resynchronization therapy was associated with reduced all-cause mortality overall (aHR 0.76; 95% CI 0.60-0.97; P=0.03).
Why the study?
Does adding an implantable cardioverter-defibrillator to cardiac resynchronization therapy reduce all-cause mortality in patients with heart failure and wide QRS?
Observational (n=917)
No
Does adding an implantable cardioverter-defibrillator to cardiac resynchronization therapy reduce all-cause mortality in patients with heart failure and wide QRS?
Adding an implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in patients with ischaemic cardiomyopathy, but not in those with non-ischaemic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Associated survival benefit should not yet change practice; leaves open need for randomized confirmation.
AIMS: Cardiac resynchronization therapy (CRT) improves symptoms, left ventricular function, and survival in patients with heart failure (HF) and wide QRS. The benefit of adding implantable cardioverter-defibrillator (ICD) backup is debated. We analysed the long-term outcome of patients with HF due to ischaemic cardiomyopathy (ICM) or non-ischaemic cardiomyopathy (NICM) treated with a CRT device with or without defibrillator backup. METHODS AND RESULTS: In this observational study, consecutive patients with an ejection fraction ≤35% and QRS width ≥120 ms receiving a CRT device at Aarhus University Hospital, Denmark from 2000 to 2010 were included. Baseline characteristics were retrieved from patient files and survival data were obtained from the Danish Civil Registration System. The primary outcome was all-cause mortality. The effect of ICD backup was estimated using Cox proportional hazards model, and the multivariate analyses were adjusted for a priori selected variables. We included 917 HF patients, 427 with NICM, and 490 with ICM. Median follow-up was 4.0 years. Adjusted hazard ratio (aHR) for all-cause mortality was 0.76 [95% confidence interval (95% CI), 0.60-0.97; P = 0.03] in all patients; 0.96 (95% CI, 0.60-1.51; P = 0.85) in patients with NICM, and 0.74 (95% CI, 0.56-0.97; P = 0.03) in patients with ICM. In patients with NICM, ICD backup seemed to be associated with improved survival among non-responders to CRT (P = 0.08), but not among responders (P = 0.61). CONCLUSION: Adding an ICD backup is associated with better survival in CRT recipients. This effect was evident among patients with ICM, but not in patients with NICM.
No takes yet. Share an insight, caveat, or question.
Witt et al. (2015) conducted an observational in Heart failure due to ischaemic or non-ischaemic cardiomyopathy (n=917). Implantable cardioverter-defibrillator (ICD) backup vs. CRT without ICD backup was evaluated on All-cause mortality (aHR 0.76, 95% CI 0.60-0.97, p=0.03). Adding an implantable cardioverter-defibrillator backup to cardiac resynchronization therapy was associated with reduced all-cause mortality overall (aHR 0.76; 95% CI 0.60-0.97; P=0.03).
Synapse has enriched 10 related papers. Consider them for comparative context: